Key Drivers
- Strong Margins
- Weak Earnings
- Receivables Drag
AIAI Summary
Phreesia is now a real cash-generating healthcare workflow platform with operating leverage, but after the revenue guidance reset and litigation overhang, the stock remains a “prove-it” story where only sustained free cash flow and durable growth above the lower bar can justify a premium multiple.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •Weak Earnings
- •Receivables Drag
PHR looks like a cash-generative but fundamentally challenged name: strong gross margins and free cash flow are offset by weak profitability, heavy receivables dependence, and limited tangible balance-sheet support.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Resistance overhead
- •Support holding
PHR is modestly trending higher after rebounding from the $8.77-$8.78 support area, but it still needs a breakout above $10.17 to confirm further upside.
Sharp drop from $10.17 on 2026-05-08 to $8.77 on 2026-05-15 showed notable volatility
Sentiment & News
Key News Insights:
- •Revenue growth
- •Litigation overhang
- •Guidance concerns
Phreesia delivered a solid Q1 FY2027 operating update with revenue and profitability growth, but the stock remains pressured by ongoing shareholder litigation and disclosure concerns around its growth outlook.
The results support the business thesis, but legal risk and prior guidance cuts may keep investor sentiment cautious in the near term
Similar Companies in Healthcare
Other companies in the same sector with AI ratings